Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Herpes Zoster (HZ) Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

NCT02052596
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

NCT02979639
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 23, 2026, 6:20 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

NCT06581575
View directory record Official record
Conditions
Herpes Zoster (HZ), Infectious Diseases, Shingles
Interventions
JCXH-105, Shingrix
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • Long Beach, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541
View directory record Official record
Conditions
Herpes Zoster (HZ), Shingles, Infectious Disease
Interventions
JCXH-105, Active Control (Shingrix)
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
32
States / cities
Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jul 23, 2026, 6:20 AM EDT
Terminated No phase listed Observational

Solid Organ Transplant SHINGRIX

NCT03993717
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
SHINGRIX
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Golden, Colorado • Wichita, Kansas • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

NCT01165229
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
70 Years and older
Enrollment
14,819 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jul 23, 2026, 6:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800
View directory record Official record
Conditions
Herpes Zoster
Interventions
mRNA-1468, Placebo, Shingrix
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
19
States / cities
Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 6:20 AM EDT
Completed No phase listed Observational Results available

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

NCT03563183
View directory record Official record
Conditions
Herpes Zoster
Interventions
Encoding of data collected in Zoster 006 and Zoster 022 studies
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
26,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Mesa, Arizona • Phoenix, Arizona • Spring Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Jul 23, 2026, 6:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.

NCT06903078
View directory record Official record
Conditions
Herpes Zoster (HZ), Vascular Dementia
Interventions
Not listed
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Houston, Texas • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

NCT02114333
View directory record Official record
Conditions
Shingles, Herpes Zoster
Interventions
Zostavax, HZ/su vaccine, Placebo
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Jul 23, 2026, 6:20 AM EDT
Recruiting Phase 3 Interventional

Shingrix in Renal Transplant Recipients

NCT04128189
View directory record Official record
Conditions
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
Interventions
Shingrix
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 6:20 AM EDT
Completed No phase listed Observational Results available

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Not listed
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

NCT02723773
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
7,539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Jul 23, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Jul 23, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jul 23, 2026, 6:20 AM EDT